Pubblicazioni dal 2001 al 2011
2011
Giorgio Cocconi, Corrado Boni, Maurizio Tonato, Rodolfo Passalacqua, Mariantonietta Colozza, Anna M. Mosconi, Giancarlo Bisagni, Ermanno Rondini, Lina Rodinò, Amalia Carpi, Francesco Di Costanzo, Mauro Brugia, Giuseppe Attardo, Luigi Acito, Riccardo Rossetti, Maria Bella, Roberta Camisa, Francesco Cardinale, Beatrice Dozin.
Randomized Trial Comparing Cyclophosphamide, Methotrexate, and 5-Fluorouracil (CMF) Regimen with Rotational CMFEV Regimen (E = Epirubicin, V = Vincristine) as Adjuvant Chemotherapy in Moderate Risk Operable Breast Carcinoma.
Journal of Cancer Therapy 2, 342-353, 2011. (IF=0.14)
Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Veer LV, Rubio IT, Viale G, Thompson AM, Passalacqua R, Nitz U, Vindevoghel A, Pierga JY, Ravdin PM, Werutsky G, Cardoso F.
The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase
Eur J Cancer. 2011 Dec;47(18):2742-9.
doi: 10.1016/j.ejca.2011.09.016. Epub 2011 Nov 1
Luca Gianni, Urania Dafni, Richard D Gelber, Evandro Azambuja, Susanne Muehlbauer, Aron Goldhirsch, Michael Untch, Ian Smith, José Baselga, Christian Jackisch, David Cameron, Max Mano, José Luiz Pedrini, Andrea Veronesi, Cesar Mendiola, Anna Pluzanska, Vladimir Semiglazov, Eduard Vrdoljak, Michael J Eckart, Zhenzhou Shen, George Skiadopoulos, Marion Procter, Kathleen I Pritchard, Martine J Piccart-Gebhart, and Richard Bell, for the Herceptin Adjuvant (HERA) Trial Study Team
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
Lancet Oncol 2011; 12: 236–44
2010
Passalacqua R, Buzio C, Buti S, Porta C, Labianca R, Pezzuolo D, Camisa R, Sabbatini R, Benecchi L, Messina C, Cengarle R, Vaglio A, Dalla Chiesa M, Tomasello G, Caminiti C.
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer.
Cancer Immunol Immunother 59: 553–561, 2010 (IF=3.791)
Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F; Gruppo Oncologico Italia Meridionale (GOIM); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.
J Clin Oncol. 2010 Apr 1;28(10):1645-51.
Buti S, Lazzarelli S, Chiesa MD, Simonelli C, Lo Re G, Lheshi A, Simon S, Mattioli R, Caminiti C, Mazza G, Donini M, Passalacqua R; from the GOIRC (Italian Oncology Group for Clinical Research).
Dose-finding Trial of a Combined Regimen With Bevacizumab, Immunotherapy, and Chemotherapy in Patients With Metastatic Renal Cell Cancer: An Italian Oncology Group for Clinical Research (GOIRC) Study.
J Immunother 33 (7): 735-41, 2010 (IF=3.203)
Cocconi G, Caminiti C, Zaninetta G, Passalacqua R, Cascinu S, Campione F, Todeschini R, Zani S, D’Aloia T, Migone L
National survey of medical choices in caring for terminally ill patients in Italy, a cross-sectional study
Tumori, 96: 122-130, 2010
2009
Passalacqua R, Caminiti C, Campione F, Diodati F, Todeschini R, Bisagni G, Labianca R, Dalla Chiesa M, Bracci R, Aragona M, Artioli F, Cavanna L, Masina A, De Falco F, Marzocchini B, Iacono C, Contu A, Di Costanzo F, Bertetto O, Annunziata MA.
Prospective, multicenter, randomized trial of a new organizational modality for providing information and support to cancer patients.
J Clin Oncol. 2009 Apr 10;27(11):1794-9.
2008
Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, Cortesi E, Carlini P, Bracci R, Tomao S, Messerini L, Arcangeli A, Torri V, Bilancia D, Floriani I, Tonato M; Italian Oncology Group for Cancer Research, Dinota A, Strafiuso G, Corgna E, Porrozzi S, Boni C, Rondini E, Giunta A, Monzio Compagnoni B, Biagioni F, Cesari M, Fornarini G, Nelli F, Carboni M, Cognetti F, Enzo MR, Piga A, Romiti A, Olivetti A, Masoni L, De Stefanis M, Dalla Mola A, Camera S, Recchia F, De Filippis S, Scipioni L, Zironi S, Luppi G, Italia M, Banducci S, Pisani Leretti A, Massidda B, Ionta MT, Nicolosi A, Canaletti R, Biscottini B, Grignani F, Di Costanzo F, Rovei R, Croce E, Carroccio R, Gilli G, Cavalli C, Olgiati A, Pandolfi U, Rossetti R, Natalini G, Foa P, Oldani S, Bruno L, Cascinu S, Catalano G, Catalano V, Lungarotti F, Farris A, Sarobba MG, Trignano M, Muscogiuri A, Francavilla F, Figoli F, Leoni M, Papiani G, Orselli G, Antimi M, Bellini V, Cabassi A, Contu A, Pazzola A, Frignano M, Lastraioli E, Saggese M, Bianchini D, Antonuzzo L, Mela M, Camisa R.: On behalf of Italian Oncology Group for Cancer Research.
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
J Natl Cancer Inst. 2008 Mar 19;100(6):388-98.
Tomasello G, de Azambuja E, Dinh P, Snoj N, Piccart-Gebhart M.
Jumping higher: is it still possible? The ALTTO trial challenge.
Expert Rev Anticancer Ther. 2008 Dec;8(12):1883-90.
2007
Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study.
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
Lancet 369 (9561): 559-70, 2007; Erratum in: Lancet 369 (9565): 906, 2007. (IF=30.758)
Dalla Chiesa M, Passalacqua R, Michiara M, Franciosi V, Di Costanzo F, Bisagni G, Camisa R, Buti S, Tommasello G, Cocconi G; Italian Oncology Group for Clinical Research.
Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomized, multicentre trial.
Acta Biomed 78 (3): 204-209, 2007
2006
Di Costanzo F, Gasperoni S, Papaldo P, Bilancia D, Manzione L, Landucci E, Mazzoni F, Cognetti F.
Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL.
Annals of Oncology 17 (1): 79-84, 2006 (IF=5.647)
2005
Sobrero A, Frassineti G, Falcone A, Dogliotti L, Rosso R, Di Costanzo F, Bruzzi P; INTACC.
Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer.
British Journal of Cancer 92 (1): 24-29, 2005.; errata corrige in Br J Cancer. 93: 733, 2005 (IF=4.346)
Di Costanzo F, Carlini P, Doni L, Massidda B, Mattioli R, Iop A, Barletta E, Moscetti L, Recchia F, Tralongo P, Gasperoni S.
Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian Oncology Group for Clinical Research (GOIRC).
British Journal of Cancer 93 (2): 185-189, 2005. (IF=4.346)
Cocconi, B. Di Blasio, C. Boni, G. Bisagni, E. Rondini, M. A. Bella, F. Leonardi, L. Savoldi, C. Vallisneri, R. Camisa, P. Bruzzi, on behalf of the Italian Oncology Group for Clinical Research (GOIRC).
Primary chemotherapy in operable breast carcinoma comparing CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with an anthracycline-containing regimen: short-term responses translated into long-term.
Annals of Oncology 16: 1469-1476, 2005 (IF=5.647)
Colozza M, Sidoni A, Mosconi AM, Cavaliere A, Bisagni G, Gori S, De Angelis V, Frassoldati A, Cherubini R, Bian AR, Rodino C, Mazzocchi B, Mihailova Z, Bucciarelli E, Tonato M; Italian Oncology Group for Clinical Research.
HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results.
Clin Breast Cancer. 6(3): 253-9, 2005. (IF=2.065)
Perrone F, Marangolo M, Di Costanzo F, Colucci G, Repetto L, Merlano M, De Placido S, Torri V, Comella G, Labianca R, Parisi V, Gallo C.
Cost of insurance policies for investigator-initiated cancer clinical trials in Italy
Tumori 91 (4): 373-373, 2005 (IF=0.863)
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
N Engl J Med. 2005 Oct 20;353(16):1659-72. doi: 10.1056/NEJMoa052306.PMID: 16236737
2004
Coombes RC, E Hall, LJ Gibson, M Phil, R Paridaens, J Jassem, T Delozier, SE Jones, I Alvarez, G Bertelli, O Ortmann, AS Coates, E Bajetta, D Dodwell, RE Coleman, LJ Fallowfield, E Mickiewicz, J Andersen, PE Lonning, G Cocconi, A Stewart, N Stuart, CF Snowdon, M Carpentieri, G Massimini, JM Bliss for the Intergroup Exemestane Study.
A randomized trial of Exemestane after two to three years of Tamoxifen therapy in postmenopausal women with primary breast cancer.
N Engl J Med 350: 1081-1092, 2004. (IF=47.050)
Di Costanzo F, Manzione L, Gasperoni S, Bilancia D, Acito L, Angiona S, Mazzoni F, Giustini L; Italian Oncology Group for Cancer Research.
Paclitaxel and mitoxantrone in metastatic breast cancer: a phase II trial of the Italian Oncology Group for Cancer Research.
Cancer Invest. 22 (3): 331-337, 2004. (IF=2.105)
Perrone F, Marangolo M, Di Costanzo F, Colucci G, Repetto L, Merlano M, De Placido S, Torri V, Comella G, Labianca R, Parisi V, Gallo C.
Insurance for independent cancer trials.
Annals of Oncology 15 (11):1722-1723, 2004. (IF=5.647)
2003
Cocconi G., Passalacqua R., Foladore S., Carlini P., Acito L., Maiello E., Marchi M., Gebbia V., Di Sarra S., Beretta M., Bacchi M.
Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, or vindesine plus tamoxifen: a prospective randomized study.
Melanoma Research 13: 73-79, 2003. (IF=2.061)
G. Cocconi, P. Carlini, A. Gamboni, S. Gasperoni, C. Rodinò, S. Zironi, G. Bisagni, S. Porrozzi, F. Cognetti, F. Di Costanzo, R. Canaletti, E. M. Ruggeri, R. Camisa, F. Pucci.
Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma.
Annals of Oncology 14: 1258-1263, 2003. (IF=5.647)
G. Cocconi.
Adjuvant chemotherapy in early breast cancer: optimal and suboptimal anthracycline-containing regimens.
Breast Cancer Research and Treatment 80: 313-320, 2003. (IF=4.696)
Di Costanzo F, Sobrero A, Gasperoni S, Dogliotti L, Frassineti L, Falcone A, Lionetto R, Bruzzi P, Luppi G, Gallo L, Conte P, Comandone A, Turci D, Marzola M, Folco U, Pfanner E, Mestriner M, Boni C, Galli C, Tonato M, Rosso R; Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC).
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC).
Annals of Oncology 14:1365-72, 2003. (IF=5.647)
2002
Cocconi G., Di Blasio B., Boni C., Bisagni G., Ceci G., Rondini E., Bella M., Leonardi F., Savoldi L., Camisa R., Bruzzi P.
Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cancer 95: 228-235, 2002. (IF=5.418)
Colozza M., Bisagni G., Mosconi A. M., Gori S., Boni C., Sabbatini R., Frassoldati A., Passalacqua R., Rosa Bian A., Rodinò C., Rondini E., Algeri R., Di Sarra S., De Angelis V., Cocconi G., Tonato M., on behalf of the Italian Oncology Group for Clinical Research (GOIRC).
Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study.
European Journal of Cancer 38: 2279-2288, 2002. (IF=4.121).
2001
Zeuli M., Pino M.S., Cognetti F.
La capecitabina nel trattamento del carcinoma colorettale.
Tumori 87 (1 suppl. 1): 55-56, 2001. (IF=0.863)
Zeuli M., Di Costanzo F., Sdrobolini A., Gasperoni S., Paoloni F.P., Carpi A., Moscetti L., Cherubini R., Cognetti F. on behalf of Gruppo Oncologico Italiano per la Ricerca Clinica (GOIRC) e Gruppo Oncologico Laziale (GOL).
Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.
Annals of Oncology 12: 1737-1741, 2001 (IF=5.647)